Having this condition is a common problem in neoadjuvant breast cancer treatment, namely the question of what to do if the disease progresses after neoadjuvant chemotherapy. There is no standard answer to this question. The 2014 NCCN guidelines are: 1) change to another chemotherapy regimen; 2) switch to radiotherapy. In my personal clinical practice, I mostly recommend switching to another chemotherapy regimen for the following reasons: 1) Although there is sufficient evidence from clinical trials that switching to another chemotherapy regimen will definitely result in tumor shrinkage, our clinical experience suggests that there are still some patients whose tumors are in remission with a different regimen after the initial regimen has failed; 2) The German GEPARTRIO trial tells us that switching to another regimen may improve patient survival. 2. The German GEPARTRIO trial tells us that changing to another regimen may improve patient survival. Therefore, my personal preference is to switch to another regimen. However, there is no objection to switching radiotherapy or surgery.